Halozyme Therapeutics (HALO) Other Non-Current Assets (2012 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Other Non-Current Assets of $15.3 million for Q1 2026, up 3.8% year-over-year from $14.7 million in Q1 2025, and up 487.81% quarter-over-quarter from $2.6 million in Q4 2025.
Halozyme Therapeutics (HALO) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Other Non-Current Assets for 15 consecutive years, with $15.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 3.8% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $15.3 million (up 3.8% YoY), while the FY2025 annual figure was $2.6 million, changed N/A from the prior year.
- Other Non-Current Assets advanced to $15.3 million in Q1 2026 per HALO's latest filing, from $2.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $56.4 million in Q2 2025 and bottomed at $500000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $18.0 million across 5 years, with a median of $15.9 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 96.77% — and 2023, when it jumped 1384.8%.
- Halozyme Therapeutics' Other Non-Current Assets stood at $500000.0 in 2022, then surged by 3523.0% to $18.1 million in 2023, then decreased by 8.56% to $16.6 million in 2024, then sank by 84.3% to $2.6 million in 2025, then jumped by 487.81% to $15.3 million in 2026.
- Business Quant data shows HALO's Other Non-Current Assets at $15.3 million in Q1 2026, $2.6 million in Q4 2025, and $55.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 55.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.09 Mn |
| Mar 31, 2026 | 15.29 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Sep 30, 2025 | 55.70 Mn |
| Jun 30, 2025 | 56.37 Mn |
| Mar 31, 2025 | 14.73 Mn |
| Sep 30, 2024 | 16.56 Mn |
| Jun 30, 2024 | 21.30 Mn |
| Mar 31, 2024 | 17.32 Mn |
| Sep 30, 2023 | 18.12 Mn |
| Mar 31, 2023 | 7.42 Mn |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 25.78 Mn |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 2.10 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 15.48 Mn |
| Mar 31, 2021 | 500,000.00 |
| Dec 31, 2020 | 4.78 Mn |